News
News
Local News
Crime & Public Safety
Your Tax Dollars At Work
Politics
Massachusetts
Nation
World
Business
Health
Weather
Columnists
Traffic
Sports
Sports
Red Sox
Patriots
Celtics
Bruins
College
High School
More Sports
Scores & Stats
Entertainment
Entertainment
Celebrity News
Arts & Culture
Movies
Television
Music
Fun & Games
Horoscope
Lottery
Comics
Puzzles
Lifestyle
Lifestyle
Food & Beverage
Travel
Style & Fashion
Obituaries
Obituaries
Local Obituaries
Submit an Obituary
Opinion
Opinion
Editorials
Op-Ed
Letters
Submit a Letter
Radio
Weather
E-Edition
Subscribe
Sign Up For Newsletters
News
News
Local News
Crime & Public Safety
Your Tax Dollars At Work
Politics
Massachusetts
Nation
World
Business
Health
Weather
Columnists
Traffic
Sports
Sports
Red Sox
Patriots
Celtics
Bruins
College
High School
More Sports
Scores & Stats
Entertainment
Entertainment
Celebrity News
Arts & Culture
Movies
Television
Music
Fun & Games
Horoscope
Lottery
Comics
Puzzles
Lifestyle
Lifestyle
Food & Beverage
Travel
Style & Fashion
Obituaries
Obituaries
Local Obituaries
Submit an Obituary
Opinion
Opinion
Editorials
Op-Ed
Letters
Submit a Letter
Radio
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Ardelyx, Inc.
< Previous
1
2
Next >
Ardelyx Appoints Experienced Biopharma Executive, Eric Foster, as Chief Commercial Officer
August 08, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx Reports Second Quarter 2024 Financial Results and Provides Business Update
August 01, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx Announces Publication of Two Plain Language Summaries from XPHOZAH® (tenapanor) Clinical Trials in Current Medical Research and Opinion
July 31, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx to Report Second Quarter 2024 Financial Results on August 1, 2024
July 18, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx, AAKP and NMQF File Lawsuit to Protect Dialysis Patient Choice and Timely Access to Clinically Meaningful Medicines
July 17, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
To Preserve Patient Access to XPHOZAH®, Ardelyx Chooses Not to File for TDAPA
July 02, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx Presents Additional Data Detailing Educational Needs Related to IBS-C Management Across Healthcare Disciplines
June 28, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx, Inc. Reports Employment Inducement Grants
May 30, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference
May 22, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
May 21, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)
May 16, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx, Inc. Reports Employment Inducement Grants
May 14, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference
May 07, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update
May 02, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the National Kidney Foundation 2024 Spring Clinical Meetings
May 01, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx to Report First Quarter 2024 Financial Results on May 2, 2024
April 18, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx, Inc. Reports Employment Inducement Grants
March 28, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy
March 25, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx, Inc. Reports Employment Inducement Grants
March 12, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx to Participate at the Cowen 44th Annual Health Care Conference
February 27, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 22, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
February 01, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx, Inc. Reports Employment Inducement Grants
January 12, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx Provides Update on Growing Commercial Momentum and 2024 Strategic Priorities
January 08, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx to Provide Company Update on IBSRELA® and Host a KOL Discussion on the IBS-C Landscape on Monday, January 8
January 03, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx, Inc. Reports Employment Inducement Grants
December 20, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx, Inc. Reports Employment Inducement Grants
November 21, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference
November 21, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hyperphosphatemia
November 15, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx Announces Departure of Board Member
November 13, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close